Skip to main content

Advertisement

SpringerLink
Log in

Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis

  • Journal Club
  • Published:
Purinergic Signalling Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Data sharing is not applicable in this case no datasets were generated or analysed in the generation of this article.

References

  1. Davenport AJ, Neagoe I, Bräuer N, Koch M, Rotergi A, Nagel J, Laux-Biehlmann A, Machet F, Coelho AM, Boyce S, Carty N, Gemkow MJ, Hess SD, Zollner TM, Fischer OM (2021) Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers. Sci Rep 11:19877. https://doi.org/10.1038/s41598-021-99177-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cockayne D, Hamilton S, Zhu QM et al (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407:1011–1015. https://doi.org/10.1038/35039519

    Article  CAS  PubMed  Google Scholar 

  3. Cockayne DA, Dunn PM, Zhong Y et al (2005) P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol 567:621–639. https://doi.org/10.1113/jphysiol.2005.088435

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Novakovic SD, Kassotakis LC, Oglesby IB, Smith JAM, Eglen RM, Ford APDW, Hunter JC (1999) Immunocytochemical localization of P2X3 purinoceptors in sensory neurons in naive rats and following neuropathic injury. Pain 22(10):273–282. https://doi.org/10.1016/S0304-3959(98)00225-5

    Article  Google Scholar 

  5. Pijacka W, Moraes D, Ratcliffe L et al (2016) Purinergic receptors in the carotid body as a new drug target for controlling hypertension. Nat Med 22:1151–1159. https://doi.org/10.1038/nm.4173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Smith JA, Kitt MM, Morice AH et al (2020) Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet 8(8):775–785. https://doi.org/10.1016/S2213-2600(19)30471-0

    Article  CAS  Google Scholar 

  7. Richards D, Gever JR, Ford AP, Fountain SJ (2019) Action of MK-7264 (Gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. Br J Pharmacol 176:2279–2291. https://doi.org/10.1111/bph.14677

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Morice A, Smith JA, McGarvey L et al (2021) Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J 58(5):2004240. https://doi.org/10.1183/13993003.04240-2020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Maddern J, Grundy L, Castro J, Brierley SM (2020) Pain in Endometriosis. Front Cell Neurosci 14:335. https://doi.org/10.3389/fncel.2020.590823

    Article  CAS  Google Scholar 

  10. Ding S, Zhu L, Tian Y, Zhu T, Huang X, Zhang X (2017) P2X3 receptor involvement in endometriosis pain via ERK signaling pathway. PLoS ONE 12(9):e0184647. https://doi.org/10.1371/journal.pone.0184647

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

MCF was supported by the UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Norwich Research Park Biosciences Doctoral Training Partnership as a CASE award in collaboration with AstraZeneca.

Author information

Authors and Affiliations

  1. Biomedical Research Centre, School of Biological Sciences, University of East Anglia, Norwich, UK

    Michelle C. Fletcher

Authors
  1. Michelle C. Fletcher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle C. Fletcher.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants or animals performed by the author.

Conflict of interest

The author declares no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fletcher, M.C. Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis. Purinergic Signalling 18, 1–3 (2022). https://doi.org/10.1007/s11302-021-09831-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11302-021-09831-5

Search

Navigation